The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Down Syndrome, Partial Trisomy 21, and Absence of Alzheimer’s Disease: The Role of APP
Open accessAbstract
Overexpression of the amyloid precursor protein (APP) gene on chromosome 21 in Down syndrome (DS) has been linked to increased brain amyloid levels and early-onset Alzheimer’s disease (AD). An elderly man with phenotypic DS and partial trisomy of chromosome 21 (PT21) lacked triplication of APP affording an opportunity to study the role of this gene in the pathogenesis of dementia. Multidisciplinary studies between ages 66–72 years comprised neuropsychological testing, independent neurological exams, amyloid PET imaging with 11 C-Pittsburgh compound-B (PiB), plasma amyloid-β (Aβ) measurements, and a brain autopsy examination. The clinical phenotype was typical for DS and his intellectual disability was mild in severity. His serial neuropsychological test scores showed less than a 3% decline as compared to high functioning individuals with DS who developed dementia wherein the scores declined 17–28% per year. No dementia was detected on neurological examinations. On PiB-PET scans, the patient with PT21 had lower PiB standard uptake values than controls with typical DS or sporadic AD. Plasma Aβ 42 was lower than values for demented or non-demented adults with DS. Neuropathological findings showed only a single neuritic plaque and neurofibrillary degeneration consistent with normal aging but not AD. Taken together the findings in this rare patient with PT21 confirm the obligatory role of APP in the clinical, biochemical, and neuropathological findings of AD in DS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and is in part a result of triplication of the amyloid precursor protein gene (APP) on Hsa21, which results in the increased production of the amyloid-β peptide and other APP gene products [12, 54].”
From Apolipoprotein E abundance is elevated in the brains of individuals with Down syndrome–Alzheimer’s disease (2025) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Down syndrome–Alzheimer’s disease (DSAD) is the most commonly occurring single genetic cause of AD”
From Apolipoprotein E abundance is elevated in the brains of individuals with Down syndrome–Alzheimer’s disease (2025) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Importantly here, we know that raised APP abundance in our DSAD cases is driven by the additional copy of APP on Hsa21, as indicated by both human-genetics studies and preclinical modelling [12, 54, 58].”
From Apolipoprotein E abundance is elevated in the brains of individuals with Down syndrome–Alzheimer’s disease (2025) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“a disorder in which an early onset form of AD invariably develops due mainly to a third copy of APP present on trisomic chromosome 21 (Korbel et al., 2009;Doran et al., 2017;Colacurcio et al., 2018).”
From Lysosomal Dysfunction in Down Syndrome Is APP-Dependent and Mediated by APP-βCTF (C99) (2019) · cites this paper as Doran et al., 2017
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This strong gene-dosage effect reinforces the amyloid cascade hypothesis and provides a natural human model of genetically driven amyloidopathy [152, 153].”
From Toward a Unified Framework in Molecular Neurobiology of Alzheimer’s Disease: Revisiting the Pathophysiological Hypotheses (2026) · cites this paper as [152]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Simple Sequentially Rejective Multiple Test Procedure
(1979) · Scandinavian Journal of Statistics · doi:10.2307/4615733 · Cited by 21,526
Tzourio-Mazoyer, N., Landeau, B., Papathanassiou, D., Crivello, F., Etard, O., Delcroix, N., Mazoyer, B., & Joliot, M. (2002) · NeuroImage · doi:10.1006/nimg.2001.0978 · Cited by 16,319
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Jenkinson, M., Bannister, P., Brady, M., & Smith, S. (2002) · NeuroImage · doi:10.1006/nimg.2002.1132 · Cited by 11,888
Jenkinson, M., Beckmann, C. F., Behrens, T. E. J., Woolrich, M. W., & Smith, S. M. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2011.09.015 · Cited by 11,314
A global optimisation method for robust affine registration of brain images
Jenkinson, M., & Smith, S. M. (2001) · Medical Image Analysis · doi:10.1016/s1361-8415(01)00036-6 · Cited by 7,018
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459
Hyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092
Montine, T. J., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., Mirra, S. S., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0910-3 · Cited by 2,894
Flagged first, then by citations
Research works printed but not linked: 10
- Korenberg JR, 1990, Am J Hum Genet, 47, 236
- Devlin L, 2004, Ulster Med J, 73, 4
- Ossendorf M, 2000, Qiagen News, 1, 11
- Wechsler D, 1997, WAIS-III administration and scoring manual
- Sparrow S, 2005, Vineland adaptive behavior scales: (Vineland II), survey interview form/caregiver rating form
- Weiner MW, 2014, Alzheimers Dement, 1, S226
- Holm S, 1979, Scand J Stat, 6, 65
- R Core Team, 2014, A Language and Environment for Statistical Computing
- Rohn TT, 2014, J Parkinsons Dis Alzheimers Dis, 1, 7
- Epstein CJ, 1991, Am J Hum Genet, 49, 207
Cited by
Sorted by citations
Items 101–200 of 244
McLachlan, M., Bettcher, B., McVea, A. K., DiFilippo, A. H., Zammit, M. D., LeMerise, L., Rouanet, J. P., Price, J. C., Tudorascu, D., Laymon, C. M., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70141 · Cited by 14
Self-citationThe history of Down syndrome–associated Alzheimer's disease; past, present, and future
Maure‐Blesa, L., Carmona‐Iragui, M., Lott, I. T., Head, E., Wısnıewskı, T., Rafii, M. S., Espinosa, J. M., Flórez, J., Mobley, W. C., Holland, A. J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70158 · Cited by 12
Self-citationLong‐distance regressive signaling in neural development and disease
Pathak, A., Clark, S. A., Bronfman, F. C., Deppmann, C. D., & Carter, B. D. (2020) · Wiley Interdisciplinary Reviews Developmental Biology · doi:10.1002/wdev.382 · Cited by 12
Castro, M. A., Parson, K. F., Beg, I., Wilkinson, M. C., Nurmakova, K., Levesque, I., Voehler, M., Wolfe, M. S., Ruotolo, B. T., & Sanders, C. R. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101792 · Cited by 13
Plasma NT1‐tau and Aβ42 correlate with age and cognitive function in two large Down syndrome cohorts
Stern, A. M., Pelt, K. L. V., Liu, L., Anderson, A. K., Ostaszewski, B. L., Mapstone, M. E., O’Bryant, S. E., Petersen, M. E., Christian, B. T., Handen, B. L., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13382 · Cited by 11
Self-citationTTC3-Mediated Protein Quality Control, A Potential Mechanism for Cognitive Impairment
Zhou, X., Chen, X., Hong, T., Zhang, M., Cai, Y., & Cui, L. (2021) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-021-01060-z · Cited by 10
The amyloid-β peptide: Guilty as charged?
Murphy, M. P., Buzinova, V. A., & Johnson, C. E. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166945 · Cited by 12
Drug-Targeted Genomes: Mutability of Ion Channels and GPCRs
Raines, R., McKnight, I., White, H., Legg, K., Lee, C., Li, W., Lee, P. H. U., & Shim, J. W. (2022) · Biomedicines · doi:10.3390/biomedicines10030594 · Cited by 10
Jin, M., Xu, R., Alam, M. M., Ma, Z., Zhu, S., Wang, L., Martini, A. C., Bernabucci, M., Xie, P., Kwan, K. Y., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3985173 · Cited by 10
Self-citationFarrell, C., Buhidma, Y., Mumford, P., Heywood, W. E., Hällqvist, J., Flores-Aguilar, L., Andrews, E. J., Rahimzadah, N., Taso, O. S., Doran, E., et al. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02889-0 · Cited by 9
“We also had the opportunity to measure APOE abundance in the frontal cortex from an individual who had partial trisomy without the APP gene region [12].”
Self-citationThirumalai, S., Livesey, F. J., Patani, R., & Hung, C. (2025) · Alzheimer's & Dementia · doi:10.1002/alz.14560 · Cited by 9
Zhou, Y., Sheehan, R., Guo, L., & Strydom, A. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70135 · Cited by 10
Chen, X., Zuo, X., Becker, A., Mante, M., Florio, J. B., Jadhav, S. G., Albay, R., Johnstone, A. D., Karachentsev, D., Rissman, R. A., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70022 · Cited by 9
Increased plasma DYRK1A with aging may protect against neurodegenerative diseases
Delabar, J. M., Lagarde, J., Fructuoso, M., Mohammad, A., Bottlaender, M., Doran, E. W., Lott, I. T., Rivals, I., Schmitt, F. A., Head, E., et al. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02419-0 · Cited by 9
Self-citationChen, X., Zuo, X., Becker, A., & Mobley, W. C. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70046 · Cited by 9
Delineating the topography of amyloid-associated cortical atrophy in Down syndrome
Mak, E., Padilla, C., Annus, T., Wilson, L. R., Hong, Y. T., Fryer, T. D., Coles, J., Aigbirhio, F. I., Menon, D. K., Nestor, P. J., et al. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.02.018 · Cited by 10
Stringer, C. A., Miyasato, H., Camey, K., Ghadia, K. A., Andrews, E. J., Ngo, P. T., Pascual, J. R., Wright, S. T., Silva, J. A., Gawronski, B., et al. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.107114 · Cited by 8
Self-citationVictorino, D. B., Faber, J., Pinheiro, D. J. L. L., Scorza, F. A., de Almeida, A.-C. G., Costa, A. C. S., & Scorza, C. A. (2022) · Aging and Disease · doi:10.14336/ad.2022.0906 · Cited by 8
Perspectives on pain in Down syndrome
Shaikh, A., Li, Y., & Lu, J. (2023) · Medicinal Research Reviews · doi:10.1002/med.21954 · Cited by 10
Vieira, W. F., Coelho, D. R. A., Gersten, M. B., Puerto, A. M. H., Kalli, S., González-Garibay, G., McEachern, K. M., Clancy, J. A., Skotko, B. G., Abbeduto, L., et al. (2024) · Photonics · doi:10.3390/photonics11070670 · Cited by 9
Xicota, L., Dang, L. T., Lee, A. E., Krinsky‐McHale, S. J., Pang, D. I., Melilli, L., O’Bryant, S. E., Henson, R. L., Laymon, C. M., Lai, F., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105433 · Cited by 8
Self-citationFrom the lab to the people: major challenges in the biological treatment of Down syndrome
Rondal, J. A. (2021) · AIMS neuroscience · doi:10.3934/neuroscience.2021015 · Cited by 8
Alldred, M. J., Ibrahim, K. W., Pidikiti, H., Chiosis, G., Mufson, E. J., Stutzmann, G. E., & Ginsberg, S. D. (2024) · Acta Neuropathologica Communications · doi:10.1186/s40478-024-01891-z · Cited by 7
Pizzano, S., Sterne, G. R., Veling, M. W., Xu, L. A., Hergenreder, T., & Ye, B. (2023) · Disease Models & Mechanisms · doi:10.1242/dmm.049725 · Cited by 7
Alldred, M. J., Pidikiti, H., Ibrahim, K. W., Lee, S. H., Heguy, A., Hoffman, G. E., Roussos, P., Wısnıewskı, T., Węgiel, J., Stutzmann, G. E., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02768-0 · Cited by 8
Editorial: Down Syndrome, Neurodegeneration and Dementia
Mufson, E. J., Ginsberg, S. D., Ma, T., Ledreux, A., & Perez, S. E. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.791044 · Cited by 7
Sharma, A., & Singh, T. G. (2025) · Brain Research · doi:10.1016/j.brainres.2025.150047 · Cited by 7
Liu, R., Guo, L., Zhao, Y., Yu, J., Yu, J., & Liu, P. (2024) · Brain Research · doi:10.1016/j.brainres.2024.148847 · Cited by 7
Acton, D., Jaydeokar, S., Taylor, R., & Jones, S. (2024) · Journal of Intellectual Disabilities · doi:10.1177/17446295241259076 · Cited by 7
Illouz, T., Ascher, L. A. B., Madar, R., & Okun, E. (2024) · Scientific Reports · doi:10.1038/s41598-024-66855-8 · Cited by 7
CaMKII mechanisms that promote pathological LTP impairments
Larsen, M. E., Rumian, N. L., Quillinan, N., & Bayer, K. U. (2025) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2024.102961 · Cited by 6
Thorwald, M. A., Godoy-Lugo, J. A., Kerstiens, E., Garcia, G., Kim, M., Shemtov, S. J., Silva, J. A., Durra, S., O’Day, P. A., Mack, W. J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70322 · Cited by 6
Self-citationCTAD taskforce: genetic therapies in Alzheimer’s disease
Jakabek, D., Isaacs, A. M., Strooper, B. D., Tuszynski, M. H., Lane, R. M., Uspenskaya, O., McDade, E., Rafii, M. S., & Mummery, C. J. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100269 · Cited by 7
The effects of Cstb duplication on APP/amyloid-β pathology and cathepsin B activity in a mouse model
Wu, Y., Whittaker, H. T., Noy, S., Cleverley, K., Brault, V., Hérault, Y., Fisher, E., & Wiseman, F. K. (2021) · PLoS ONE · doi:10.1371/journal.pone.0242236 · Cited by 5
Cognitive outcome measures for tracking Alzheimer's disease in Down syndrome
Fleming, V., Hom, C. L., Clare, I. C. H., Hurd-Thomas, S. L., Krinsky‐McHale, S. J., Handen, B. L., & Hartley, S. L. (2022) · International review of research in developmental disabilities · doi:10.1016/bs.irrdd.2022.05.006 · Cited by 8
A pilot exploration with Posiphen to normalize amyloid precursor protein in Down syndrome
Chen, X. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.313044 · Cited by 6
Li, W., Wang, X., & Li, S. (2018) · Molecular Cytogenetics · doi:10.1186/s13039-018-0391-3 · Cited by 6
Raza, M. A., Folz, A., Victorino, D. B., Xing, Z., Chen, X., Zuo, X., Borden, L. K., Potier, M., Mobley, W. C., Dierssen, M., et al. (2026) · STAR Protocols · doi:10.1016/j.xpro.2026.104717 · Cited by 7
McVea, A. K., DiFilippo, A. H., McLachlan, M., Betcher, B., Zammit, M. D., Betthauser, T. J., Converse, A. K., Murali, D., Stone, C. K., Hartley, S. L., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70357 · Cited by 5
Self-citationHat die Alzheimer-Forschung versagt?
Haass, C., & Levin, J. (2019) · Der Nervenarzt · doi:10.1007/s00115-019-0751-1 · Cited by 5
Chromosomal and cellular therapeutic approaches for Down syndrome: A research update
Huang, T., Fakurazi, S., Cheah, P.-S., & Ling, K. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150664 · Cited by 6
Aging with Intellectual Disability: Dementia and Cognitive Decline
Sheerin, F. K., McCallion, P., McGlinchey, E., O’Dwyer, M., Reilly, E., & McCarron, M. (2020) · Autism and child psychopathology series · doi:10.1007/978-3-030-46835-4_19 · Cited by 5
Triplication of Synaptojanin 1 in Alzheimer’s Disease Pathology in Down Syndrome
Hwang, R., Dang, L. T., Chen, J., Lee, J. H., & Marquer, C. (2022) · Current Alzheimer Research · doi:10.2174/1567205020666221202102832 · Cited by 5
Guo, Z., Xiao, H., Yang, W., Li, T., Hao, B., & Liao, S. (2023) · Aging · doi:10.18632/aging.205291 · Cited by 5
What Can We Learn About Alzheimer’s Disease from People with Down Syndrome?
Maure‐Blesa, L., Rodríguez‐Baz, Í., Carmona‐Iragui, M., & Fortea, J. (2024) · Current topics in behavioral neurosciences · doi:10.1007/7854_2024_546 · Cited by 5
Monitoring cognition in people with epilepsy and intellectual disability
Catalán‐Aguilar, J., Witt, J., & Helmstaedter, C. (2025) · Seizure · doi:10.1016/j.seizure.2025.06.021 · Cited by 4
Age and sex are associated with Alzheimer's disease neuropathology in Down syndrome
Andrews, E. J., Ngo, P. T., Pascual, J. R., Gonzalez, F., Phelan, M. J., Wright, S. T., Harp, J. P., Schmitt, F. A., Lai, F., Lao, P. J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70408 · Cited by 4
Self-citationCharacterization of neurodegenerative pathologies in adult and pediatric subjects with Down syndrome
Canan, F., Wick, N., Raisanen, J. M., Burns, D. K., Hatanpaa, K. J., Richardson, T. E., White, C. L., & Daoud, E. V. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251362762 · Cited by 4
Tau pathology differs by sex in Alzheimer's disease in Down syndrome
Chen, X., Zuo, X., & Mobley, W. C. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70838 · Cited by 6
Costa, A. C. S. (2024) · Brain Sciences · doi:10.3390/brainsci14111084 · Cited by 4
Age‐related cardiovascular disease in Down syndrome: A population‐based matched cohort study
Pedersén, A., Nordenvall, A. S., Tettamanti, G., & Nordgren, A. (2025) · Journal of Internal Medicine · doi:10.1111/joim.20093 · Cited by 4
Leptin levels are associated with body mass index and Alzheimer's disease in Down syndrome
Sordo, L., Du, A. X., Sandadi, V., Dustagheer, F. B., Pascual, J. R., Ngo, P., Hom, C. L., Doran, E. W., & Head, E. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70448 · Cited by 3
Self-citationFilgueira, M. M., Díaz, S. P., & López, A. I. (2019) · Revista Española de Discapacidad · doi:10.5569/2340-5104.07.02.09 · Cited by 4
Loosli, S. V., Schmidt, L., Nübling, G., Wlasich, E., Prix, C., Danek, A., & Levin, J. (2021) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-1362-9868 · Cited by 5
Overk, C., Fiorini, E., Babolin, C., Vukicevic, M., Morici, C., Madani, R., Eligert, V., Kosco‐Vilbois, M. H., Roberts, A. J., Becker, A., et al. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1202208 · Cited by 4
Cannavo, C., Tosh, J., Fisher, E., & Wiseman, F. K. (2019) · Progress in brain research · doi:10.1016/bs.pbr.2019.10.004 · Cited by 4
Substrate interaction inhibits γ-secretase production of amyloid-β peptides
Zhao, J., Xiao, Y., Liu, X., Kim, S., Wu, X., Barros, M., Zhuang, R., Hou, X., Zhang, Y., Robakis, N. K. R. K., et al. (2020) · Chemical Communications · doi:10.1039/c9cc09170j · Cited by 4
Kutasi, E., Chiş, A., Vințan, M. A., Alkhzouz, C., Văduva, D. A., Catana, A. M., & Vulturar, R. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05245-1 · Cited by 5
Factors Associated With Alzheimer's Dementia Diagnosis and Survival in Down Syndrome
Pounds, O., Theodore, K., & Dodd, K. (2025) · Journal of Intellectual Disability Research · doi:10.1111/jir.13230 · Cited by 3
U1‐70K and U1A and tau pathogenesis in demented and non‐demented individuals with Down syndrome
Perez, S. E., Miguel, J. C., Nadeem, M., Malek‐Ahmadi, M. H., Hales, C. M., Head, E., & Mufson, E. J. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70474 · Cited by 2
Self-citationAmir, M., Shafi, S., Parveen, S., Reshi, A. A., & Ahmad, A. (2024) · Pharmaceuticals · doi:10.3390/ph17081090 · Cited by 3
Alzheimer's risk and quality of life: History of Down syndrome as a case in point
Silverman, W. P., & Krinsky‐McHale, S. J. (2021) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12171 · Cited by 3
Barros‐Santos, B., Campos‐Marques, C., Salvador, A. F., & Silva, J. M. (2025) · Brain Organoid and Systems Neuroscience Journal · doi:10.1016/j.bosn.2025.04.006 · Cited by 2
Physical activity as a resistance or resilience mechanism in Down syndrome Alzheimer's disease
Fleming, V., Peven, J. C., Helsel, B. C., Ptomey, L. T., Clina, J. G., Barry, A., Ances, B. M., Handen, B. L., Christian, B. T., Laymon, C. M., et al. (2025) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70127 · Cited by 2
Self-citationDevelopment of Molecular Neuropathology in Down Syndrome across the Lifespan
Bhattacharyya, A., de la Torre-Ubieta, L., Zhu, Y., Head, E., Swarup, V., & Sousa, A. M. M. (2025) · Journal of Neuroscience · doi:10.1523/jneurosci.1365-25.2025 · Cited by 3
Self-citationClinical trials for Alzheimer's disease in Down syndrome
Rafii, M. S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818845-3.00017-7 · Cited by 2
Ebbing, K., von Gunten, A., Guinchat, V., Georgescu, D., Bersier, T., Moad, D., & Verloo, H. (2022) · Disabilities · doi:10.3390/disabilities2040047 · Cited by 2
Barraza, N., Pérez-Núñez, R., Gaete‐Ramírez, B., Barrios-Garrido, A., Arriagada, C., Poksay, K. S., John, V., Barnier, J., Cárdenas, A. M., & Caviedes, P. A. (2023) · Neurotoxicity Research · doi:10.1007/s12640-023-00638-3 · Cited by 2
Recent Advances in Alzheimer’s Disease Treatments with Therapeutic Antibodies to Amyloid-β
Yang, J., & Bradford, A. (2022) · Journal of Student Research · doi:10.47611/jsrhs.v11i3.3453 · Cited by 2
Bio-Metal Dyshomeostasis-Associated Acceleration of Aging and Cognitive Decline in Down Syndrome
Ishihara, K., Kawashita, E., & Akiba, S. (2023) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b23-00131 · Cited by 2
Unique Pathology in the Locus Coeruleus of Individuals with Down Syndrome
Saternos, H., Hamlett, E. D., Guzman, S. J., Head, E., Granholm, A., & Ledreux, A. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240043 · Cited by 2
Self-citationGrill, J. D., & Rabinovici, G. D. (2025) · JAMA · doi:10.1001/jama.2025.3372 · Cited by 2
Lioudyno, M., Sevrioukov, E. A., Olivarria, G. M., Hitchcock, L., Javonillo, D. I., Campos, S. M., Rivera, I., Wright, S. T., Head, E., Fortea, J., et al. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02895-2 · Cited by 3
Self-citationDown syndrome: a model for chromosome abnormalities
Overk, C., & Mobley, W. C. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85654-6.00007-1 · Cited by 4
Nerve Growth Factor Compromise in Down Syndrome
Carmo, S. D., Kannel, B., & Cuello, A. C. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.719507 · Cited by 2
Fluid biomarkers for Alzheimer's disease in Down syndrome: Current status and novel trends
Iulita, M. F., Granholm, A., Carmona‐Iragui, M., Hamlett, E. D., Fortea, J., & Ledreux, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818845-3.00010-4 · Cited by 2
New insights into the effects of APP gene dose on synapse in Down syndrome
Chen, X., & Zuo, X. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.382245 · Cited by 2
Revista Española de Discapacidad
(2019) · Revista Española de Discapacidad · doi:10.5569/2340-5104.07.02 · Cited by 2
A Neuropathology Case Report of a Woman with Down Syndrome who Remained Cognitively StablePreprint
Liou, J., Lou, J. J., Nakagiri, J., Yong, W. H., Hom, C. L., Doran, E. W., Totoiu, M. O., Lott, I. T., Mapstone, M. E., Keator, D. B., et al. (2024) · medRxiv · doi:10.1101/2024.06.01.24308050 · Cited by 2
Self-citationAPP Gene-based Strategies to Combat Alzheimer's Disease in Down Syndrome
Chen, X. (2025) · Current Genomics · doi:10.2174/0113892029360836250127103637 · Cited by 2
Sun, C., Thomas, R. W., Stringer, C. A., Galani, K., Ho, L., Sun, N., Renfro, A., Wright, S. T., Firenze, R. M., Tsai, L., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.17.719050 · Cited by 2
Self-citationExploring A Decade of Research on Down Syndrome: A Bibliometric Analysis
George, R. J., Manoj Kumar, L., Unnikrishnan, D. T., Kunjavara, J., & Sam, S. T. (2024) · National Journal of Community Medicine · doi:10.55489/njcm.150420243588 · Cited by 1
Alzheimer's Disease Research Center Down Syndrome Cores: Experience from two sites
Ptomey, L. T., Hom, C. L., Wilkins, H., Doran, E. W., Wright, S. T., Hoang, D., Delehoy, B., Lott, I. T., Perales‐Puchalt, J., Helsel, B. C., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70612 · Cited by 1
Self-citationCross‐Sectional FDG in Down Syndrome and Autosomal Dominant Alzheimer's Disease
Abdelmoity, O., Wisch, J. K., Kennedy, J. T., Goyal, M. S., Vlassenko, A. G., Flores, S. E., Handen, B. L., Head, E., Keator, D. B., Rafii, M. S., et al. (2025) · Annals of Neurology · doi:10.1002/ana.78002 · Cited by 1
Self-citationKwak, Y., Yang, S., Yuk, M., Oh, K., Lee, C., Lee, T., Kim, H. J., Kim, B.-G., Kang, M., Park, H., et al. (2026) · GeroScience · doi:10.1007/s11357-026-02154-6 · Cited by 1
Genetic Modulators of Disease Penetrance
Kang, Y., & Drivas, T. G. (2026) · Annual Review of Biomedical Data Science · doi:10.1146/annurev-biodatasci-103123-094547 · Cited by 1
Aguilar, L. F., Zaikos, T. D., Rivera, I., Wright, S. T., Lou, J., Gawronski, B., Gonzalez, L., Berry, J. V., Rouanet, J. P., Edwards, N. C., et al. (2026) · Acta Neuropathologica · doi:10.1007/s00401-026-03028-z · Cited by 1
Self-citationA plasma protein signature for cerebral amyloid angiopathy
Singh, A., Denkinger, M. N., Leuzy, A., Dieckhoff, K., Liu, J., Marques, T. M., Monuki, E. S., Stark, C., Grill, J. D., Hom, C. L., et al. (2026) · Acta Neuropathologica · doi:10.1007/s00401-026-03030-5 · Cited by 1
Self-citationIshihara, K., Yasui, H., Harada, K., Amano, K., Saito, M., Kaneda, K., Katsuda, M., Kawashita, E., Hata, T., Annoura, R., et al. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261469121 · Cited by 1
Genetics of Alzheimer's disease in adults with Down syndrome
Lee, J. H., Dang, L. T., Pang, D. I., Krinsky‐McHale, S. J., & Schupf, N. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818845-3.00001-3 · Cited by 1
What We Should Not Forget about Down Syndrome
Fragoso, D. C., Nunes, D. M., Maia, A. C. M., Garcia, L. A. L., Alves, H. C. B. R., da Silva, C. J., & Leite, C. C. (2021) · Neurographics · doi:10.3174/ng.2000043 · Cited by 2
Novel Pharmacological Approach to the Treatment of Alzheimer’s Disease
-, M. S. D., & -, P. T. J. (2022) · International Journal For Multidisciplinary Research · doi:10.36948/ijfmr.2022.v04i06.1069 · Cited by 1
Desai, S., Chen, I. Y., Hom, C., Doran, E., Nguyen, D., Benca, R., Lott, I., & Mander, B. (2024) · Journal of Alzheimer's Disease · doi:10.3233/jad-220750 · Cited by 1
Self-citationNeuropathology of trisomy 21 mosaicism in a case with early‐onset dementia
Ngo, P. T., Pascual, J. R., Wright, S. T., Williams, C. K., Magaki, S., Yong, W. H., Vinters, H. V., Ringman, J. M., & Head, E. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14394 · Cited by 1
Self-citationWagemann, O., Brendel, M., Franzmeier, N., Nübling, G., Gnörich, J. S., Zaganjori, M., Prix, C., Stockbauer, A., Wlasich, E., Loosli, S. V., et al. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1505999 · Cited by 1
Zigman, W. B., Krinsky‐McHale, S. J., Schupf, N., Urv, T. K., & Silverman, W. P. (2017) · Springer eBooks · doi:10.1007/978-3-319-61720-6_6 · Cited by 1
Poirier, M. B., Hadwen, J., & MacKenzie, A. (2019) · Emerging Topics in Life Sciences · doi:10.1042/etls20180099 · Cited by 1
Modeling Down Syndrome Neurodevelopment with Dosage Compensation
Czerminski, J. T. (2019) · eScholarship@UMassChan · doi:10.13028/j7xf-1q21 · Cited by 1
Hat die Alzheimer-Forschung versagt?: Das Scheitern amyloidbasierter klinischer Studien
Haass, C., & Levin, J. (2019) · Der Nervenarzt · Cited by 1
Jin, M., Xu, R., Wang, L., Alam, M. M., Ma, Z., Zhu, S., Martini, A. C., Jadali, A., Bernabucci, M., Xie, P., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.22.473858 · Cited by 1
Self-citation
Metadata
- Authors
- Doran, E., Keator, D., Head, E., Phelan, M. J., Kim, R., Totoiu, M., Barrio, J. R., Small, G. W., Potkin, S. G., & Lott, I. T.
- Affiliations
- University of California, Irvine Medical Center (US)
- University of California, Irvine (US)
- University of Kentucky (US)
- University of California, Los Angeles (US)
- Corresponding author
- Lott, Ira T.
- ORCID
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2016-12-09
- Volume
- 56
- Issue
- 2
- Pages
- 459-470
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC5662115
- OpenAlex
- W2567009735
- Cited by
- 244
- References
- 68
- Citations by year
- 2026: 16 · 2025: 45 · 2024: 35 · 2023: 25 · 2022: 31 · 2021: 28 · 2020: 21 · 2019: 27 · 2018: 11 · 2017: 5
- FWCI
- 11.53
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Alzheimer s Disease (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (UL1TR000153)
- National Institute on Aging (P50AG016573, R01AG021912, U01AG051412, R01AG033015, U19AG068054, U24AG021886)
- National Institute of Mental Health (U01MH097435)
- National Center for Research Resources (U24RR021992, P20RR020837)
- National Center for Advancing Translational Sciences
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD065160, R01HD064993)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Down syndrome and intellectual disability research
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Down syndrome, partial trisomy 21
- MeSH terms
- Aged, Alzheimer Disease, Brain, Down Syndrome, Humans, Male, Phenotype, Amyloid beta-Protein Precursor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
